Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.

Jayantee Kalita Usha Kant MisraSarvesh K ChaudharyMoromi DasAnadi MishraAbhay RanjanMritunjai Kumar

Published in: European journal of neurology (2022)

IVIg is beneficial in AIDP variants of GBS but not in the AMAN subtype. A customized treatment may be cost-effective until a randomized controlled trial is conducted in AMAN.

Keyphrases

case report
gene expression
dna methylation
low dose
genome wide